INVE vs BMEA Comparison

Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.